<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical presentation, diagnosis, and staging evaluation of neuroblastoma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical presentation, diagnosis, and staging evaluation of neuroblastoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical presentation, diagnosis, and staging evaluation of neuroblastoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jason M Shohet, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jed G Nuchtern, MD, FACS, FAAP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer H Foster, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Julie R Park, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 16, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The term neuroblastoma is commonly used to refer to a spectrum of neuroblastic tumors (including neuroblastomas, ganglioneuroblastomas, and ganglioneuromas) that arise from primitive sympathetic ganglion cells and, like paragangliomas and pheochromocytomas, have the capacity to synthesize and secrete catecholamines. (See  <a class="medical medical_review" href="/d/html/5231.html" rel="external">"Paragangliomas: Epidemiology, clinical presentation, diagnosis, and histology"</a> and  <a class="medical medical_review" href="/d/html/130.html" rel="external">"Clinical presentation and diagnosis of pheochromocytoma"</a>.)</p><p>Neuroblastomas, which account for 97 percent of all neuroblastic tumors, are heterogeneous, varying in terms of location, histopathologic appearance, and biologic characteristics [<a href="#rid1">1</a>]. They are most remarkable for their broad spectrum of clinical behavior, which can range from spontaneous regression, to maturation to a benign ganglioneuroma, or aggressive disease with metastatic dissemination leading to death [<a href="#rid2">2</a>].</p><p>Clinical diversity correlates closely with numerous clinical and biological factors (including patient age, tumor stage and histology, and genetic and chromosomal abnormalities). For example, most infants with disseminated disease have a favorable outcome following treatment with chemotherapy and/or surgery, although the majority of children older than one year of age with advanced-stage disease die from progressive disease despite intensive multimodality therapy. This clinical complexity likely derives from the developmental origins of neuroblastoma, which arises due to developmental arrest of maturing components of the embryonic neural crest [<a href="#rid3">3</a>].</p><p>Neuroblastoma has been associated with central hypoventilation, Hirschsprung disease, and neurofibromatosis type 1 (neurocristopathy syndrome), and as a familial disorder associated with mutations in the anaplastic lymphoma kinase (<em>ALK</em>) gene. These are discussed separately. (See  <a class="medical medical_review" href="/d/html/5204.html" rel="external">"Epidemiology, pathogenesis, and pathology of neuroblastoma"</a>.)</p><p>The clinical presentation, diagnosis, and staging evaluation of neuroblastoma will be presented here. The epidemiology, pathogenesis, pathology, treatment, and prognosis of neuroblastoma are presented separately. (See  <a class="medical medical_review" href="/d/html/5204.html" rel="external">"Epidemiology, pathogenesis, and pathology of neuroblastoma"</a> and  <a class="medical medical_review" href="/d/html/5203.html" rel="external">"Treatment and prognosis of neuroblastoma"</a>.)</p><p>Olfactory neuroblastoma, a malignancy of the olfactory epithelium, which has a different cell of origin, presentation, and treatment than neuroblastoma, is also discussed separately. (See  <a class="medical medical_review" href="/d/html/5183.html" rel="external">"Olfactory neuroblastoma (esthesioneuroblastoma)"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>Neuroblastomas can arise anywhere throughout the sympathetic nervous system. The adrenal gland is the most common primary site (40 percent), followed by abdominal (25 percent), thoracic (15 percent), cervical (5 percent), and pelvic sympathetic ganglia (5 percent)  (<a class="graphic graphic_diagnosticimage graphicRef72000" href="/d/graphic/72000.html" rel="external">image 1</a>) [<a href="#rid4">4</a>]. Less commonly, tumors arise within the central or autonomic nervous systems [<a href="#rid1">1</a>]. In approximately 1 percent of cases, a primary tumor cannot be identified. Neuroblastoma metastasizes to lymph nodes, bone marrow, cortical bone, dura, orbits, liver, and skin, and less frequently to pulmonary and intracranial sites  (<a class="graphic graphic_diagnosticimage graphicRef79453" href="/d/graphic/79453.html" rel="external">image 2</a> and <a class="graphic graphic_diagnosticimage graphicRef62275" href="/d/graphic/62275.html" rel="external">image 3</a>) [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Presenting symptoms</span><span class="headingEndMark"> — </span>The presenting symptoms reflect the location of the primary tumor and the extent of metastatic disease, if present. Patients with localized disease can be asymptomatic, whereas children with advanced disease appear ill at presentation, usually with systemic symptoms.</p><p>Signs and symptoms of neuroblastoma may include [<a href="#rid6">6-8</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Abdominal mass (retroperitoneal or hepatic)</p><p class="bulletIndent1"><span class="glyph">●</span>Abdominal pain or constipation</p><p class="bulletIndent1"><span class="glyph">●</span>Proptosis</p><p class="bulletIndent1"><span class="glyph">●</span>Periorbital ecchymoses ("raccoon eyes," from periorbital ecchymosis caused by orbital metastases)</p><p class="bulletIndent1"><span class="glyph">●</span>Horner syndrome (miosis, ptosis, anhidrosis)</p><p class="bulletIndent1"><span class="glyph">●</span>Cord compression (lower extremity weakness, changes in reflexes, ascending paralysis)</p><p class="bulletIndent1"><span class="glyph">●</span>Unexplained back pain, dysuria, constipation</p><p class="bulletIndent1"><span class="glyph">●</span>Palpable nontender subcutaneous nodules</p><p class="bulletIndent1"><span class="glyph">●</span>Opsoclonus myoclonus syndrome</p><p class="bulletIndent1"><span class="glyph">●</span>Otherwise unexplained secretory diarrhea (from paraneoplastic production of vasoactive intestinal polypeptide [VIP])</p><p class="bulletIndent1"><span class="glyph">●</span>Systemic symptoms (fever, weight loss)</p><p class="bulletIndent1"><span class="glyph">●</span>Bone pain</p><p class="bulletIndent1"><span class="glyph">●</span>Anemia</p><p class="bulletIndent1"><span class="glyph">●</span>Heterochromia iridis (different colors of the iris or portions of the iris)</p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension</p><p class="bulletIndent1"><span class="glyph">●</span>Additional clinical evidence for neuroblastoma (eg, adrenal mass on ultrasound examination, elevated urine catecholamines)</p><p></p><p class="headingAnchor" id="H4"><span class="h3">Abdominal tumors</span><span class="headingEndMark"> — </span>Approximately two-thirds of primary neuroblastomas arise in the abdomen; among these, approximately two-thirds are from the adrenal glands [<a href="#rid2">2,7</a>]. Abdominal tumors can present with abdominal pain or fullness, abdominal mass, hypertension, or rarely intestinal obstruction. When the primary tumor arises from the organs of Zuckerkandl (a pair of embryonic organs that persist until shortly after birth and are located near the aortic bifurcation), the child may have symptoms related to compression of the bowel or bladder (eg, constipation, reduced bladder capacity, enuresis) [<a href="#rid2">2</a>]. Large abdominal tumors also can compress venous or lymphatic drainage, leading to scrotal and lower extremity edema. A sudden and dramatic increase in tumor size with abdominal distention and discomfort can result from spontaneous hemorrhage into the tumor [<a href="#rid2">2</a>].</p><p>An abdominal mass may be detected in an asymptomatic child by the primary care clinician during a routine examination. The mass is typically, but not always, non-tender, fixed, and firm. Such masses may also be detected initially using abdominal ultrasound. (See <a class="local">'Staging studies'</a> below.)</p><p>In a review of malignant abdominal masses diagnosed at a children's hospital, the mass was detected by the primary care provider during a well-child or brief acute-care visit in 11 percent of cases, highlighting the importance of the abdominal examination in all patients [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H5"><span class="h3">Thoracic tumors</span><span class="headingEndMark"> — </span>Primary thoracic tumors may be detected incidentally on radiographs obtained in the evaluation of other complaints (eg, respiratory symptoms, trauma) [<a href="#rid2">2</a>] (see <a class="local">'Paravertebral tumors'</a> below). Mediastinal tumors can cause tracheal deviation or narrowing with resultant stridor, although high thoracic and cervical masses may be associated with a Horner syndrome (ptosis, miosis, and anhidrosis) [<a href="#rid2">2</a>] (see  <a class="medical medical_review" href="/d/html/5249.html" rel="external">"Horner syndrome"</a>). Large thoracic tumors, usually associated with mechanical obstruction, may cause the superior vena cava syndrome [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/d/html/2832.html" rel="external">"Malignancy-related superior vena cava syndrome"</a>.)</p><p class="headingAnchor" id="H6"><span class="h3">Paravertebral tumors</span><span class="headingEndMark"> — </span>Because neuroblastomas may arise from paravertebral sympathetic ganglia (paraganglia), primary tumors (usually in the retroperitoneum or mediastinum) are able to invade the spinal canal through the neural foramina, creating a so-called "dumbbell" tumor  (<a class="graphic graphic_diagnosticimage graphicRef72000" href="/d/graphic/72000.html" rel="external">image 1</a>). The subsequent epidural spinal cord compression, an oncologic emergency, can cause pain, motor or sensory deficits, or loss of bowel and/or bladder control. The subtle and gradual onset of such neurologic symptoms in young children can make diagnosis difficult. (See  <a class="medical medical_review" href="/d/html/2819.html" rel="external">"Clinical features and diagnosis of neoplastic epidural spinal cord compression"</a>.)</p><p>Involvement of the cervical paravertebral sympathetic chain and inferior cervical (stellate) ganglion can result in the Horner syndrome (ipsilateral ptosis, miosis, and anhidrosis) [<a href="#rid10">10,11</a>] (see  <a class="medical medical_review" href="/d/html/5249.html" rel="external">"Horner syndrome"</a>). Heterochromia iridis (different colors of the iris or portions of the iris) is common among infants who have congenital Horner syndrome, but also occurs in acquired cases [<a href="#rid12">12</a>]. In one retrospective review of 405 cases of neuroblastoma, unilateral Horner syndrome was present in 14 children (3 percent) and was the presenting sign in nine (2 percent) [<a href="#rid13">13</a>].</p><p>Infants with isolated or acquired Horner syndrome should undergo careful examination for cervical and abdominal masses, as well as a measurement of urinary catecholamine metabolites, vanillylmandelic acid (VMA) and homovanillic acid (HVA) [<a href="#rid12">12,14</a>]. Radiologic evaluation of the head, neck, and chest is warranted for those who have acquired Horner syndrome, or whose Horner syndrome is associated with other signs (eg, increasing heterochromia, cervical mass, other cranial nerve palsies). (See <a class="local">'Is there a role for neuroblastoma screening?'</a> below.)</p><p>In a retrospective review of 23 infants with an isolated Horner syndrome, urinary VMA was measured in 21, and radiographic imaging (computed tomography [CT] or magnetic resonance imaging [MRI]) of the chest and neck undertaken in 12 [<a href="#rid12">12</a>]. Previously undetected pathology was found in two infants (one with cervical neuroblastoma and another with a benign ganglioneuroma of the left pulmonary apex); a third had been diagnosed with abdominal neuroblastoma before presenting for evaluation of Horner syndrome. Four infants were thought to have birth trauma as an explanation for their Horner syndrome, and no underlying cause was identified among the remaining 16; no additional pathology developed among these patients after a mean 9.3 years of follow-up.</p><p class="headingAnchor" id="H7"><span class="h2">Catecholamine secretion</span><span class="headingEndMark"> — </span>As neuroblastoma is derived from neural crest cells that are destined to form components of the peripheral sympathetic nervous system, they frequently express both the norepinephrine transporter gene (NAT, making them metaiodobenzylguanidine [MIBG] avid) and the enzymes required for catecholamine metabolism. (See <a class="local">'Staging studies'</a> below.)</p><p>Degradation of norepinephrine, epinephrine, and dopamine lead to the final end products VMA and HVA. Elevated levels of VMA and HVA can be detected in the serum and urine of approximately 70 to 90 percent of patients with neuroblastoma [<a href="#rid15">15</a>]. Testing for these products using high-performance liquid chromatography or other methods can thus be a highly sensitive and specific aid in making the diagnosis of a variety of neuroendocrine tumors including pheochromocytoma and neuroblastoma [<a href="#rid16">16,17</a>]. (See <a class="local">'Urine catecholamines'</a> below.)</p><p class="headingAnchor" id="H8"><span class="h2">Paraneoplastic syndromes</span><span class="headingEndMark"> — </span>Several unique paraneoplastic syndromes can be associated with both localized and disseminated neuroblastomas.</p><p class="headingAnchor" id="H9"><span class="h3">Opsoclonus myoclonus</span><span class="headingEndMark"> — </span>Opsoclonus-myoclonus syndrome (OMS), also known as opsoclonus-myoclonus-ataxia (OMA), is a paraneoplastic syndrome that occurs in 1 to 3 percent of children with neuroblastoma. Almost 50 percent of children with OMA have an underlying neuroblastoma; neurologic symptoms precede tumor diagnosis in about half of these. The disorder is believed to have an autoimmune pathogenesis.</p><p>The characteristic symptoms of OMA are rapid, dancing eye movements, rhythmic jerking (myoclonus) involving limbs or trunk, and/or ataxia.</p><p>All children with OMA must be evaluated for neuroblastoma [<a href="#rid18">18</a>]. If the initial evaluation is unrevealing, it should be repeated in several months.</p><p>The pathogenesis, clinical features, evaluation, treatment, and prognosis of paraneoplastic OMA are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/15861.html" rel="external">"Opsoclonus-myoclonus-ataxia syndrome", section on 'Pediatric syndrome'</a>.)</p><p class="headingAnchor" id="H10"><span class="h3">Secretion of VIP</span><span class="headingEndMark"> — </span>Autonomous tumor secretion of vasoactive intestinal polypeptide (VIP) is another paraneoplastic syndrome that is rarely associated with neuroblastoma. VIP secretion can cause abdominal distension and intractable secretory diarrhea with associated hypokalemia [<a href="#rid19">19</a>]; these symptoms usually resolve after removal of the tumor [<a href="#rid20">20</a>].</p><p>The diagnosis of a VIP-secreting tumor is established by the presence of an otherwise unexplained high-volume secretory diarrhea and a serum VIP concentration in excess of 75 pg/mL. A single elevated VIP level should be confirmed by additional testing. VIP-producing tumors are more often the less aggressive ganglioneuroblastomas and ganglioneuromas rather than undifferentiated neuroblastomas [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/d/html/2610.html" rel="external">"VIPoma: Clinical manifestations, diagnosis, and management"</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Metastatic disease</span><span class="headingEndMark"> — </span>Neuroblastoma metastasizes by both lymphatic and hematogenous routes. Regional lymph node involvement is found in 35 percent of children who have apparently localized disease [<a href="#rid2">2</a>]. Involvement of lymph nodes outside the cavity or region of origin (ie, abdomen, thorax, pelvis) is considered to represent disseminated disease.</p><p>Hematogenous spread extends most often to bone, bone marrow, skin, and liver. Metastatic involvement of the liver is common in infants and can cause respiratory compromise [<a href="#rid2">2</a>]. Neuroblastomas also may spread to lung and brain parenchyma, but this usually occurs as a manifestation of relapsing or end-stage disease [<a href="#rid22">22</a>].</p><p>Metastatic spread to the bones and bone marrow can cause pain (especially with ambulation), blood count abnormalities, and fever [<a href="#rid2">2,23-25</a>]. In young children, who cannot complain of pain, bone pain may manifest as a limp or unexplained irritability. Tumor infiltration of the periorbital bones, typically unilateral, can cause the characteristic periorbital ecchymosis ("raccoon eyes"), ptosis, and proptosis. In one retrospective review of 405 cases of neuroblastoma, proptosis or periorbital ecchymosis was present in 15 percent [<a href="#rid13">13</a>].</p><p>Metastatic spread to the skin manifests as papules or subcutaneous nodules that can be distributed over the entire body. These lesions are present in approximately one-third of children with congenital neuroblastoma and are typically described as firm, bluish-red, and non-tender [<a href="#rid26">26-28</a>]. The lesions have a distinctive response to rubbing, characterized by central blanching with a surrounding halo of erythema that persists for 30 to 60 minutes [<a href="#rid27">27,28</a>]. The differential diagnosis of skin nodules is presented below. Rigorous evaluation is important to determine the etiology of the nodules so that the child can be appropriately treated. Children with skin nodules that are biopsy-proven to be neuroblastoma should undergo a full tumor evaluation by an oncologist.</p><p class="headingAnchor" id="H12"><span class="h2">Prenatal diagnosis</span><span class="headingEndMark"> — </span>Obstetrical ultrasound examination is often used to detect neuroblastoma in the prenatal setting. As the ease and accuracy of third-trimester imaging with obstetrical ultrasound has improved, and the indications for these studies have broadened, the incidence of prenatal diagnosis of neuroblastoma has risen steadily [<a href="#rid29">29-31</a>]. Prenatally detected adrenal masses typically are found during ultrasound examinations performed after 32 weeks gestation, with the earliest observed at 18 weeks [<a href="#rid32">32</a>]. More than 55 cases of antenatal neuroblastoma have been reported in the literature since the original report in 1983 [<a href="#rid31">31,33</a>]. One hundred children per year in North America are diagnosed with neuroblastoma either prenatally or at younger than three months of age. Because most of these tumors are present antepartum, the incidence of prenatal diagnosis is likely to continue to rise.</p><p>If an adrenal tumor was detected on prenatal ultrasound performed for unrelated reasons and the fetus was otherwise progressing normally, repeat ultrasound after delivery should be performed. Urine catecholamines also may be helpful in distinguishing a neuroblastoma from other potential masses including adrenal hemorrhage and vascular malformations, although a negative result does not exclude the diagnosis.</p><p class="headingAnchor" id="H13"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of neuroblastoma includes a variety of neoplastic and non-neoplastic conditions and varies according to tumor location. Distinguishing these conditions from neuroblastoma may be particularly difficult in patients whose tumors do not produce catecholamines or who do not have an obvious primary tumor [<a href="#rid2">2</a>].</p><p>When the tumor arises in a suprarenal location, Wilms' tumor and hepatoblastoma should be considered. In thoracic and retroperitoneal locations, lymphoma, germ cell tumors, and infection should be considered. Metastatic involvement of the bone marrow must be distinguished from lymphoma, small cell osteosarcoma, mesenchymal chondrosarcoma, the Ewing sarcoma family of tumors, primitive neuroectodermal tumors (PNETs), undifferentiated soft-tissue sarcomas such as rhabdomyosarcoma, and leukemia, particularly megakaryoblastic leukemia. If the spinal canal is involved, either as a metastatic lesion or by extension of the primary tumor, the differential diagnosis should extend to other neurodevelopmental tumors such as desmoid tumors, epidermoid tumors, and teratomas, as well as astrocytomas [<a href="#rid34">34</a>].</p><p>Opsoclonus-myoclonus syndrome may occur in association with other conditions besides neuroblastoma [<a href="#rid35">35-45</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tumors </strong>– Hepatoblastoma</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infections </strong>– Poliovirus, parainfluenza virus, coxsackie virus B3 and B2, Epstein-Barr virus, St. Louis encephalitis virus, salmonella, Lyme disease, rickettsia, syphilis, psittacosis, and human immunodeficiency virus (HIV)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ingestions </strong>– <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">Lithium</a>, <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a>, <a class="drug drug_general" data-topicid="9345" href="/d/drug information/9345.html" rel="external">diazepam</a>, cocaine</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxic exposures </strong>– Toluene, thallium, organophosphates, chlordecone, strychnine</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolic derangements </strong>– Biotin-responsive multiple carboxylase deficiency, hyperosmolar nonketotic coma</p><p></p><p>The differential diagnosis of skin nodules in newborns and infants includes dermoid and other cysts, subcutaneous fat necrosis, benign tumors (eg, infantile myofibromatosis, congenital self-healing reticulohistiocytosis), and other malignant tumors (eg, infantile fibrosarcoma, rhabdomyosarcoma, and congenital leukemia). Biopsy may be required for definitive diagnosis. (See  <a class="medical medical_review" href="/d/html/5788.html" rel="external">"Skin nodules in newborns and infants"</a>.)</p><p>The causes of secretory diarrhea are listed in the table  (<a class="graphic graphic_table graphicRef65916" href="/d/graphic/65916.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H14"><span class="h1">DIAGNOSTIC AND STAGING EVALUATION</span><span class="headingEndMark"> — </span>In children with suspected neuroblastoma, the diagnostic evaluation is best performed at a pediatric cancer center where pediatric oncologists, surgeons, and radiologists familiar with neuroblastoma can be closely involved in the planning and coordination.</p><p class="headingAnchor" id="H3726544425"><span class="h2">Diagnostic evaluation</span><span class="headingEndMark"> — </span>All patients with suspected neuroblastoma should undergo a complete history and physical examination. Most patients will undergo laboratory evaluations including routine blood counts, serum chemistries, and tests of liver and kidney function. Evaluation of urine or serum catecholamine metabolite levels, vanillylmandelic acid (VMA), and homovanillic acid (HVA) should be obtained to assist in diagnosis and monitoring of disease response, since levels are elevated in greater than 70 to 80 percent of patients with neuroblastoma. </p><p class="headingAnchor" id="H898865188"><span class="h3">Biopsy</span><span class="headingEndMark"> — </span>The diagnosis of neuroblastoma is definitively confirmed on histology using biopsy. Care must be taken to ensure that adequate diagnostic material is obtained for complete characterization of primary tumor. The nature and extent of the initial diagnostic procedure for a child with suspected neuroblastoma should be decided only after consultation with a pediatric surgeon and oncologist who are familiar with the diagnosis and treatment of neuroblastoma. </p><p>In most patients, diagnostic tissue is usually obtained by incisional or image-guided core needle biopsy of the primary tumor [<a href="#rid46">46</a>]. A bone marrow biopsy/aspirate may be used to diagnose patients suspected to have metastatic disease involving the bone marrow. Based on the choice of biopsy technique, these principles are followed:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incisional or image-guided biopsy technique </strong>– A hollow needle guide should be placed through the skin and soft tissue superficial to the mass to avoid the need for multiple needle passes through uninvolved structures. A minimum of 25 to 30 passes with a 14- or 16-gauge core biopsy needle should be obtained. Real time pathology consultation should confirm that viable tissue is present. The hollow guide should be injected with fibrin glue sealant as the guide is withdrawn to minimize bleeding and tumor seeding of the track.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone marrow biopsy/aspirate </strong>– Bone marrow disease is evaluated by aspiration and biopsy of the bone marrow, usually at the posterior iliac crests. Two separate sites are assayed, resulting in four samples (two aspirations, two biopsies). It must contain at least 1 cm of marrow, excluding cartilage, to be considered adequate. If any of the four assays demonstrate tumor cells  (<a class="graphic graphic_picture graphicRef73187" href="/d/graphic/73187.html" rel="external">picture 1</a>), the bone marrow is considered positive for disease [<a href="#rid47">47</a>]. All four assays must be without evidence of tumor for the bone marrow to be considered clear. In a subset of cases, bone marrow biopsy may not be sufficient to guide therapy because it does not provide information about the histologic grade of the primary tumor.</p><p></p><p>Tumor tissue or bone marrow, if positive for tumor, must be evaluated for histology (favorable or unfavorable), status of the gene <em>MYCN</em>, DNA ploidy, and loss of heterozygosity (LOH) at 1p or 11q, preferably at a centralized laboratory if the treating institution does not routinely perform these analyses. Proper handling of the tissues after biopsy is crucial in determining treatment. Thus, biopsy should be undertaken with the guidance of a pediatric oncologist or pediatric surgical oncologist whenever possible. (See  <a class="medical medical_review" href="/d/html/5203.html" rel="external">"Treatment and prognosis of neuroblastoma", section on 'Risk stratification'</a>.)</p><p class="headingAnchor" id="H1654334001"><span class="h3">Urine catecholamines</span><span class="headingEndMark"> — </span>Neuroblastoma tumor cells take up and metabolize catecholamines, and the resulting degradation products can be detected in serum and urine. Urinary HVA and VMA levels are useful for both diagnosis and for monitoring disease activity over time. Screening programs for neuroblastoma using urine catecholamines are discussed below. (See <a class="local">'Is there a role for neuroblastoma screening?'</a> below.)</p><p class="headingAnchor" id="H1118799637"><span class="h2">Diagnostic criteria</span><span class="headingEndMark"> — </span>Minimum criteria for establishing a diagnosis of neuroblastoma have been agreed upon by an international consensus panel [<a href="#rid47">47</a>]. A definitive diagnosis of neuroblastoma requires one of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>An unequivocal histologic diagnosis from tumor tissue by light microscopy, with or without immunohistochemistry, electron microscopy,<strong> </strong>or increased urine (or serum) catecholamines or their metabolites</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evidence of metastases to bone marrow on an aspirate or biopsy <strong>with</strong> concomitant elevation of urinary or serum catecholamines or their metabolites</p><p></p><p class="headingAnchor" id="H16"><span class="h2">Staging studies</span><span class="headingEndMark"> — </span>In patients with suspected neuroblastoma, it is mandatory to obtain complete staging studies before beginning treatment. The goal of these studies is to evaluate the extent of disease. These findings, in turn, determine the clinical and pathologic stage, treatment, and prognosis. The evaluation is best completed at a pediatric cancer center where pediatric oncologists and radiologists familiar with neuroblastoma can be closely involved in the planning and coordination [<a href="#rid48">48</a>]. (See  <a class="medical medical_review" href="/d/html/5203.html" rel="external">"Treatment and prognosis of neuroblastoma"</a>.)</p><p>The following studies are necessary for optimal staging: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>CT or MRI</strong> – While ultrasound is often the initial radiologic study in the evaluation of a child with an abdominal mass, evaluation of the primary tumor site and nodal sites of metastatic disease by computed tomography (CT) or magnetic resonance imaging (MRI) must also be performed in suspected cases of neuroblastoma. Extension of imaging into chest and pelvis may be required in cases of retroperitoneal primary disease that can extend into these cavities, as well as to assess for potential metastatic sites of disease.</p><p></p><p class="bulletIndent1">CT or MRI of the primary tumor may reveal a heterogeneous mass, possibly containing calcifications  (<a class="graphic graphic_diagnosticimage graphicRef78302" href="/d/graphic/78302.html" rel="external">image 4</a>). When the mass is adjacent to the spine, an MRI is particularly helpful for evaluation of spinal canal invasion  (<a class="graphic graphic_diagnosticimage graphicRef72000" href="/d/graphic/72000.html" rel="external">image 1</a>).</p><p></p><p class="bulletIndent1">Additionally, a head CT or MRI should be pursued for patients presenting with proptosis, periorbital ecchymosis, or as clinically indicated by symptoms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>I123-MIBG scan versus FDG-PET</strong> – Patients with a confirmed diagnosis of neuroblastoma should be evaluated for bony metastatic disease. For such patients, I123 MIBG is preferred to FDG positron emission topography (FDG-PET) scan or technetium scan for evaluation of the bone, given its higher sensitivity and specificity for detection of metastatic disease. Among patients with known neuroblastoma, I123 MIBG has a sensitivity of approximately 90 percent [<a href="#rid49">49</a>]. For patients with a negative MIBG (indicating MIBG non-avid disease), FDG-PET scan should be performed [<a href="#rid50">50</a>]. </p><p></p><p class="bulletIndent1">MIBG can be combined with single photon emission computed tomography and CT (SPECT-CT) to better classify lesions that appear on planar MIBG scans, detect additional lesions, and better classify lesions that are near areas of physiologic MIBG uptake  (<a class="graphic graphic_diagnosticimage graphicRef131973" href="/d/graphic/131973.html" rel="external">image 5</a>) [<a href="#rid51">51</a>]. I-131 MIBG is an optional imaging reagent for SPECT-CT [<a href="#rid52">52</a>]. Additional imaging modalities and improved sensitivity will continue to improve detection of metastatic disease.</p><p></p><p class="bulletIndent1">MIBG is a chemical analog of norepinephrine that is selectively concentrated in sympathetic nervous tissues such as neuroblastoma. It can be labeled with radioactive iodine and imaged by scintigraphy. The MIBG scan is both sensitive and specific for neuroblastoma and is recommended at diagnosis and repeat evaluations of the tumor [<a href="#rid47">47,49,53-57</a>]. Because radioactive iodine is used, the thyroid gland must be protected by the simultaneous administration of nonradioactive iodine (eg, potassium iodide). When MIBG is used for treatment, thyroid dysfunction has been reported as a potential complication in up to 64 percent of patients [<a href="#rid58">58-60</a>].</p><p></p><p class="bulletIndent1">In about 10 percent of patients, bone metastases may be suspected despite a negative MIBG. In such cases, a PET scan is a sensitive tool for evaluating metastatic spread to cortical bone, although it is not routinely recommended over I123 MIBG scans. Plain radiographs are not as sensitive as bone scans because of the degree of cortical bone destruction needed to visualize a lesion on plain film.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone marrow biopsy and aspirate </strong>– Evaluation of bone marrow biopsy and aspirate should be obtained as part of staging. Further details on this technique are discussed above (See <a class="local">'Biopsy'</a> above.)</p><p></p><p class="headingAnchor" id="H634530432"><span class="h1">STAGING SYSTEM</span><span class="headingEndMark"> — </span>Neuroblastomas are staged using the International Neuroblastoma Risk Group Staging System (INRGSS)  (<a class="graphic graphic_table graphicRef88604" href="/d/graphic/88604.html" rel="external">table 2</a>), which was originally developed as part of an international collaboration to define risk based on image-defined risk factors (IDRF). These IDRF connote tumor infiltration or encasement of vital structures and correlate with the ability to achieve complete resection. Pretreatment IDRF are combined with presence or absence of metastatic spread and yield a stage for every patient  (<a class="graphic graphic_figure graphicRef108061" href="/d/graphic/108061.html" rel="external">figure 1</a>) [<a href="#rid61">61</a>]. These stages are then combined with patient age and tumor biological characteristics to assign the patient to a specific risk group. This approach was compared with the previous International Neuroblastoma Staging System and was found to be more uniformly applicable across all patient cohorts [<a href="#rid62">62</a>]. (See  <a class="medical medical_review" href="/d/html/5203.html" rel="external">"Treatment and prognosis of neuroblastoma", section on 'Staging system'</a>.)</p><p class="headingAnchor" id="H20"><span class="h1">IS THERE A ROLE FOR NEUROBLASTOMA SCREENING?</span><span class="headingEndMark"> — </span>Universal screening of infants for neuroblastoma with urine catecholamines is <strong>not</strong> recommended, as data suggest that this approach does not reduce mortality. </p><p>Screening may be considered in cases where there is a familial history of neuroblastoma. If present, analysis for germline mutation of the anaplastic lymphoma kinase (<em>ALK</em>) gene should also be performed. (See  <a class="medical medical_review" href="/d/html/5204.html" rel="external">"Epidemiology, pathogenesis, and pathology of neuroblastoma", section on 'Molecular abnormalities (prognostic impact)'</a>.)</p><p>Because outcome is significantly better for patients with localized disease and younger age, several groups have attempted to develop screening programs for neuroblastoma in infancy by measuring urinary catecholamines [<a href="#rid63">63-66</a>]. The aim of these studies has been to ascertain whether earlier detection would decrease the incidence of high-risk or advanced-stage disease and ultimately improve survival.</p><p>Four large studies from Japan, Canada, Austria, and Europe have screened over 10 million children at either six to seven months or one year of age. The incidence of neuroblastoma diagnosis was compared with historic controls [<a href="#rid64">64</a>], unscreened children from the same country [<a href="#rid66">66</a>], or unscreened populations in other cities [<a href="#rid63">63,65</a>]. All of these studies were remarkably similar:</p><p class="bulletIndent1"><span class="glyph">●</span>Screening led to more neuroblastomas being diagnosed in the screened population; however, the additional tumors were mainly low-stage tumors with favorable biologic features. Many of these tumors presumably would have undergone spontaneous regression and never would have been diagnosed clinically.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There was no decrease in the incidence of high-risk tumors in children beyond the age of screening (ie, older than one year of age).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mortality was not lower in the screened populations.</p><p></p><p>These observations were supported in a pilot study of observation in Japanese infants with neuroblastoma detected through mass screening [<a href="#rid67">67</a>]. Infants were eligible for inclusion if their tumors were stage I or II  (<a class="graphic graphic_table graphicRef73974" href="/d/graphic/73974.html" rel="external">table 3</a>), less than 5 cm in diameter, and did not involve large vessels or organs. Immediate resection was performed for increase in size, elevation of tumor markers, or evidence of metastasis. Spontaneous regression occurred in 13 of 22 cases (59 percent); eight of the remaining tumors were resected for increase in size, elevation of tumor markers, and/or parental request; and one tumor was resected at the parents' request. Among the resected tumors, five had favorable biologic features. All patients survived without recurrence. (See  <a class="medical medical_review" href="/d/html/5203.html" rel="external">"Treatment and prognosis of neuroblastoma", section on 'Prognostic factors'</a>.)</p><p>An adverse impact of screening was suggested in the study from Canada, in which 2 of the 43 patients whose tumors were detected by screening had significant adverse effects because of treatment for their favorable-prognosis neuroblastoma [<a href="#rid65">65</a>]. Another study demonstrated that expectant observation of infants younger than six months with small adrenal masses resulted in favorable event-free and overall survival outcomes for most patients, while also avoiding surgical morbidity [<a href="#rid68">68</a>].</p><p class="headingAnchor" id="H354154861"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/114548.html" rel="external">"Society guideline links: Neuroblastomas"</a>.)</p><p class="headingAnchor" id="H22"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation </strong>– Neuroblastoma should be included in the differential diagnosis of children who present with the following symptoms (see <a class="local">'Clinical presentation'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Abdominal mass (retroperitoneal or hepatic)</p><p class="bulletIndent2"><span class="glyph">•</span>Abdominal pain or constipation</p><p class="bulletIndent2"><span class="glyph">•</span>Proptosis</p><p class="bulletIndent2"><span class="glyph">•</span>Periorbital ecchymosis ("raccoon eyes")</p><p class="bulletIndent2"><span class="glyph">•</span>Horner syndrome (miosis, ptosis, anhidrosis)</p><p class="bulletIndent2"><span class="glyph">•</span>Cord compression (neurologic compromise of lower extremities)</p><p class="bulletIndent2"><span class="glyph">•</span>Unexplained back pain, dysuria, constipation</p><p class="bulletIndent2"><span class="glyph">•</span>Bladder dysfunction, constipation</p><p class="bulletIndent2"><span class="glyph">•</span>Palpable nontender subcutaneous nodules</p><p class="bulletIndent2"><span class="glyph">•</span>Opsoclonus myoclonus syndrome</p><p class="bulletIndent2"><span class="glyph">•</span>Unexplained secretory diarrhea</p><p class="bulletIndent2"><span class="glyph">•</span>Additional clinical evidence for neuroblastoma (eg, adrenal mass on ultrasound examination, elevated urine catecholamines)</p><p></p><p class="bulletIndent1">In children with signs or symptoms of neuroblastoma, the diagnostic evaluation is best performed at a pediatric cancer center where pediatric oncologists, surgeons, and radiologists familiar with neuroblastoma can be closely involved in the planning and coordination. (See <a class="local">'Diagnostic and staging evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Confirming the diagnosis </strong>– The definitive diagnosis of neuroblastoma is made by histologic confirmation, either from biopsy of tumor tissue or evidence of metastases to bone marrow on aspirate or biopsy <strong>with</strong> concomitant elevation of catecholamines in the urine. (See <a class="local">'Diagnostic evaluation'</a> above and <a class="local">'Diagnostic criteria'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Staging studies </strong>– Staging studies include computed tomography (CT) or magnetic resonance imaging (MRI) scan of the primary site and nodal sites of metastatic disease, bone imaging (preferably with a metaiodobenzylguanidine [MIBG] scan  (<a class="graphic graphic_diagnosticimage graphicRef131973" href="/d/graphic/131973.html" rel="external">image 5</a>)), and bilateral iliac crest bone marrow aspirate and biopsy. (See <a class="local">'Staging studies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Staging system </strong>– Neuroblastomas are staged using the International Neuroblastoma Risk Group Staging System (INRGSS)  (<a class="graphic graphic_table graphicRef88604" href="/d/graphic/88604.html" rel="external">table 2</a> and <a class="graphic graphic_figure graphicRef108061" href="/d/graphic/108061.html" rel="external">figure 1</a>). (See <a class="local">'Staging system'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Is there a role for neuroblastoma screening? </strong>– Universal screening of infants for neuroblastoma with urine catecholamines is <strong>not</strong> recommended, as data suggest that this approach does not reduce mortality. (See <a class="local">'Is there a role for neuroblastoma screening?'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Goodman MT, Gurney JG, Smith MA, Olshan AF. Sympathetic nervous system tumors. In: Cancer Incidence and Survival among Children and Adolescents: United States SEER Program, 1975-1995, Ries LA, Smith,MA, Gurney JG, et al (Eds), National Cancer Institute, Bethesda, MD 1999. p.35.</li><li class="breakAll">Brodeur GM, Hogarty MD, Mosse YP, Maris JM. Neuroblastoma. In: Principles and Practice of Pediatric Oncology, Pizzo PA, Poplack DG (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. p.886.</li><li><a class="nounderline abstract_t">Louis CU, Shohet JM. Neuroblastoma: molecular pathogenesis and therapy. Annu Rev Med 2015; 66:49.</a></li><li class="breakAll">Neuroblastic tumours of adrenal gland and sympathetic nervous system. In: Pathology and Genetics of Tumours of the Nervous System, World Health Organization, IARC, Lyon 2000. p.153.</li><li><a class="nounderline abstract_t">DuBois SG, Kalika Y, Lukens JN, et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol 1999; 21:181.</a></li><li><a class="nounderline abstract_t">Golden CB, Feusner JH. Malignant abdominal masses in children: quick guide to evaluation and diagnosis. Pediatr Clin North Am 2002; 49:1369.</a></li><li><a class="nounderline abstract_t">Angstman KB, Miser JS, Franz WB 3rd. Neuroblastoma. Am Fam Physician 1990; 41:238.</a></li><li><a class="nounderline abstract_t">Swift CC, Eklund MJ, Kraveka JM, Alazraki AL. Updates in Diagnosis, Management, and Treatment of Neuroblastoma. Radiographics 2018; 38:566.</a></li><li><a class="nounderline abstract_t">Ingram L, Rivera GK, Shapiro DN. Superior vena cava syndrome associated with childhood malignancy: analysis of 24 cases. Med Pediatr Oncol 1990; 18:476.</a></li><li><a class="nounderline abstract_t">Ogita S, Tokiwa K, Takahashi T, et al. Congenital cervical neuroblastoma associated with Horner syndrome. J Pediatr Surg 1988; 23:991.</a></li><li><a class="nounderline abstract_t">Woodruff G, Buncic JR, Morin JD. Horner's syndrome in children. J Pediatr Ophthalmol Strabismus 1988; 25:40.</a></li><li><a class="nounderline abstract_t">George ND, Gonzalez G, Hoyt CS. Does Horner's syndrome in infancy require investigation? Br J Ophthalmol 1998; 82:51.</a></li><li><a class="nounderline abstract_t">Musarella MA, Chan HS, DeBoer G, Gallie BL. Ocular involvement in neuroblastoma: prognostic implications. Ophthalmology 1984; 91:936.</a></li><li><a class="nounderline abstract_t">Mahoney NR, Liu GT, Menacker SJ, et al. Pediatric horner syndrome: etiologies and roles of imaging and urine studies to detect neuroblastoma and other responsible mass lesions. Am J Ophthalmol 2006; 142:651.</a></li><li><a class="nounderline abstract_t">LaBrosse EH, Com-Nougué C, Zucker JM, et al. Urinary excretion of 3-methoxy-4-hydroxymandelic acid and 3-methoxy-4-hydroxyphenylacetic acid by 288 patients with neuroblastoma and related neural crest tumors. Cancer Res 1980; 40:1995.</a></li><li><a class="nounderline abstract_t">Sadilkova K, Dugaw K, Benjamin D, Jack RM. Analysis of vanillylmandelic acid and homovanillic acid by UPLC-MS/MS in serum for diagnostic testing for neuroblastoma. Clin Chim Acta 2013; 424:253.</a></li><li><a class="nounderline abstract_t">Cangemi G, Barco S, Reggiardo G, et al. Interchangeability between 24-hour collection and single spot urines for vanillylmandelic and homovanillic acid levels in the diagnosis of neuroblastoma. Pediatr Blood Cancer 2013; 60:E170.</a></li><li><a class="nounderline abstract_t">Brunklaus A, Pohl K, Zuberi SM, de Sousa C. Investigating neuroblastoma in childhood opsoclonus-myoclonus syndrome. Arch Dis Child 2012; 97:461.</a></li><li><a class="nounderline abstract_t">Kaplan SJ, Holbrook CT, McDaniel HG, et al. Vasoactive intestinal peptide secreting tumors of childhood. Am J Dis Child 1980; 134:21.</a></li><li><a class="nounderline abstract_t">Funato M, Fujimura M, Shimada S, et al. Rapid changes of serum vasoactive intestinal peptide after removal of ganglioneuroblastoma with watery-diarrhea-hypokalemia-achlorhydria syndrome in a child. J Pediatr Gastroenterol Nutr 1982; 1:131.</a></li><li><a class="nounderline abstract_t">Davies RP, Slavotinek JP, Dorney SF. VIP secreting tumours in infancy. A review of radiological appearances. Pediatr Radiol 1990; 20:504.</a></li><li><a class="nounderline abstract_t">Cowie F, Corbett R, Pinkerton CR. Lung involvement in neuroblastoma: incidence and characteristics. Med Pediatr Oncol 1997; 28:429.</a></li><li><a class="nounderline abstract_t">Scott JP, Morgan E. Coagulopathy of disseminated neuroblastoma. J Pediatr 1983; 103:219.</a></li><li><a class="nounderline abstract_t">Labotka RJ, Morgan ER. Myelofibrosis in neuroblastoma. Med Pediatr Oncol 1982; 10:21.</a></li><li><a class="nounderline abstract_t">Quinn JJ, Altman AJ. The multiple hematologic manifestations of neuroblastoma. Am J Pediatr Hematol Oncol 1979; 1:201.</a></li><li><a class="nounderline abstract_t">Hawthorne HC Jr, Nelson JS, Witzleben CL, Giangiacomo J. Blanching subcutaneous nodules in neonatal neuroblastoma. J Pediatr 1970; 77:297.</a></li><li><a class="nounderline abstract_t">Lucky AW, McGuire J, Komp DM. Infantile neuroblastoma presenting with cutaneous blanching nodules. J Am Acad Dermatol 1982; 6:389.</a></li><li><a class="nounderline abstract_t">Wyatt AJ, Hansen RC. Pediatric skin tumors. Pediatr Clin North Am 2000; 47:937.</a></li><li><a class="nounderline abstract_t">Ho PT, Estroff JA, Kozakewich H, et al. Prenatal detection of neuroblastoma: a ten-year experience from the Dana-Farber Cancer Institute and Children's Hospital. Pediatrics 1993; 92:358.</a></li><li><a class="nounderline abstract_t">Jennings RW, LaQuaglia MP, Leong K, et al. Fetal neuroblastoma: prenatal diagnosis and natural history. J Pediatr Surg 1993; 28:1168.</a></li><li><a class="nounderline abstract_t">Acharya S, Jayabose S, Kogan SJ, et al. Prenatally diagnosed neuroblastoma. Cancer 1997; 80:304.</a></li><li><a class="nounderline abstract_t">Holgersen LO, Subramanian S, Kirpekar M, et al. Spontaneous resolution of antenatally diagnosed adrenal masses. J Pediatr Surg 1996; 31:153.</a></li><li><a class="nounderline abstract_t">Fénart D, Deville A, Donzeau M, Bruneton JN. [Retroperitoneal neuroblastoma diagnosed in utero. Apropos of 1 case]. J Radiol 1983; 64:359.</a></li><li><a class="nounderline abstract_t">Wilson PE, Oleszek JL, Clayton GH. Pediatric spinal cord tumors and masses. J Spinal Cord Med 2007; 30 Suppl 1:S15.</a></li><li><a class="nounderline abstract_t">Pranzatelli MR. The neurobiology of the opsoclonus-myoclonus syndrome. Clin Neuropharmacol 1992; 15:186.</a></li><li><a class="nounderline abstract_t">Averbuch-Heller L, Remler B. Opsoclonus. Semin Neurol 1996; 16:21.</a></li><li><a class="nounderline abstract_t">Wilfong AA, Parke JT, McCrary JA 3rd. Opsoclonus-myoclonus with Beckwith-Wiedemann syndrome and hepatoblastoma. Pediatr Neurol 1992; 8:77.</a></li><li><a class="nounderline abstract_t">Verma A, Brozman B. Opsoclonus-myoclonus syndrome following Epstein-Barr virus infection. Neurology 2002; 58:1131.</a></li><li><a class="nounderline abstract_t">Sheth RD, Horwitz SJ, Aronoff S, et al. Opsoclonus myoclonus syndrome secondary to Epstein-Barr virus infection. J Child Neurol 1995; 10:297.</a></li><li><a class="nounderline abstract_t">Vukelic D, Bozinovic D, Morovic M, et al. Opsoclonus-myoclonus syndrome in a child with neuroborreliosis. J Infect 2000; 40:189.</a></li><li><a class="nounderline abstract_t">McCarthy VP, Zimmerman AW, Miller CA. Central nervous system manifestations of parainfluenza virus type 3 infections in childhood. Pediatr Neurol 1990; 6:197.</a></li><li><a class="nounderline abstract_t">Adamolekun B, Hakim JG. Opsoclonus-myoclonus associated with traditional medicine ingestion: case report. East Afr Med J 1998; 75:120.</a></li><li><a class="nounderline abstract_t">Scharf D. Opsoclonus-myoclonus following the intranasal usage of cocaine. J Neurol Neurosurg Psychiatry 1989; 52:1447.</a></li><li><a class="nounderline abstract_t">Matsumura K, Sonoh M, Tamaoka A, Sakuta M. Syndrome of opsoclonus-myoclonus in hyperosmolar nonketotic coma. Ann Neurol 1985; 18:623.</a></li><li><a class="nounderline abstract_t">Kuban KC, Ephros MA, Freeman RL, et al. Syndrome of opsoclonus-myoclonus caused by Coxsackie B3 infection. Ann Neurol 1983; 13:69.</a></li><li><a class="nounderline abstract_t">Mohamed H, Pastor MC, Langlois S, Cowan KN. Comparing safety and adequacy between surgical biopsy versus core needle biopsy in diagnosing neuroblastoma. J Pediatr Surg 2022; 57:866.</a></li><li><a class="nounderline abstract_t">Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11:1466.</a></li><li><a class="nounderline abstract_t">Corrigan JJ, Feig SA, American Academy of Pediatrics. Guidelines for pediatric cancer centers. Pediatrics 2004; 113:1833.</a></li><li><a class="nounderline abstract_t">Vik TA, Pfluger T, Kadota R, et al. (123)I-mIBG scintigraphy in patients with known or suspected neuroblastoma: Results from a prospective multicenter trial. Pediatr Blood Cancer 2009; 52:784.</a></li><li><a class="nounderline abstract_t">Sung AJ, Weiss BD, Sharp SE, et al. Prognostic significance of pretreatment 18F-FDG positron emission tomography/computed tomography in pediatric neuroblastoma. Pediatr Radiol 2021; 51:1400.</a></li><li><a class="nounderline abstract_t">Brisse HJ, McCarville MB, Granata C, et al. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology 2011; 261:243.</a></li><li><a class="nounderline abstract_t">Theerakulpisut D, Raruenrom Y, Wongsurawat N, Somboonporn C. Value of SPECT/CT in Diagnostic I-131 MIBG Scintigraphy in Patients with Neuroblastoma. Nucl Med Mol Imaging 2018; 52:350.</a></li><li><a class="nounderline abstract_t">Shulkin BL, Shapiro B. Current concepts on the diagnostic use of MIBG in children. J Nucl Med 1998; 39:679.</a></li><li><a class="nounderline abstract_t">Perel Y, Conway J, Kletzel M, et al. Clinical impact and prognostic value of metaiodobenzylguanidine imaging in children with metastatic neuroblastoma. J Pediatr Hematol Oncol 1999; 21:13.</a></li><li><a class="nounderline abstract_t">Geatti O, Shapiro B, Sisson JC, et al. Iodine-131 metaiodobenzylguanidine scintigraphy for the location of neuroblastoma: preliminary experience in ten cases. J Nucl Med 1985; 26:736.</a></li><li><a class="nounderline abstract_t">Voute PA, Hoefnagel CA, Marcuse HR, de Kraker J. Detection of neuroblastoma with 131I-meta-iodobenzylguanidine. Prog Clin Biol Res 1985; 175:389.</a></li><li><a class="nounderline abstract_t">Taggart DR, Han MM, Quach A, et al. Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. J Clin Oncol 2009; 27:5343.</a></li><li><a class="nounderline abstract_t">van Santen HM, de Kraker J, van Eck BL, et al. High incidence of thyroid dysfunction despite prophylaxis with potassium iodide during (131)I-meta-iodobenzylguanidine treatment in children with neuroblastoma. Cancer 2002; 94:2081.</a></li><li><a class="nounderline abstract_t">Picco P, Garaventa A, Claudiani F, et al. Primary hypothyroidism as a consequence of 131-I-metaiodobenzylguanidine treatment for children with neuroblastoma. Cancer 1995; 76:1662.</a></li><li><a class="nounderline abstract_t">Garaventa A, Guerra P, Arrighini A, et al. Treatment of advanced neuroblastoma with I-131 meta-iodobenzylguanidine. Cancer 1991; 67:922.</a></li><li><a class="nounderline abstract_t">Monclair T, Brodeur GM, Ambros PF, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol 2009; 27:298.</a></li><li><a class="nounderline abstract_t">Cohn SL, Pearson AD, London WB, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009; 27:289.</a></li><li><a class="nounderline abstract_t">Schilling FH, Spix C, Berthold F, et al. Neuroblastoma screening at one year of age. N Engl J Med 2002; 346:1047.</a></li><li><a class="nounderline abstract_t">Yamamoto K, Ohta S, Ito E, et al. Marginal decrease in mortality and marked increase in incidence as a result of neuroblastoma screening at 6 months of age: cohort study in seven prefectures in Japan. J Clin Oncol 2002; 20:1209.</a></li><li><a class="nounderline abstract_t">Woods WG, Gao RN, Shuster JJ, et al. Screening of infants and mortality due to neuroblastoma. N Engl J Med 2002; 346:1041.</a></li><li><a class="nounderline abstract_t">Kerbl R, Urban CE, Ambros IM, et al. Neuroblastoma mass screening in late infancy: insights into the biology of neuroblastic tumors. J Clin Oncol 2003; 21:4228.</a></li><li><a class="nounderline abstract_t">Oue T, Inoue M, Yoneda A, et al. Profile of neuroblastoma detected by mass screening, resected after observation without treatment: results of the Wait and See pilot study. J Pediatr Surg 2005; 40:359.</a></li><li><a class="nounderline abstract_t">Nuchtern JG, London WB, Barnewolt CE, et al. A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group study. Ann Surg 2012; 256:573.</a></li></ol></div><div id="topicVersionRevision">Topic 5187 Version 32.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Goodman MT, Gurney JG, Smith MA, Olshan AF. Sympathetic nervous system tumors. In: Cancer Incidence and Survival among Children and Adolescents: United States SEER Program, 1975-1995, Ries LA, Smith,MA, Gurney JG, et al (Eds), National Cancer Institute, Bethesda, MD 1999. p.35.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Brodeur GM, Hogarty MD, Mosse YP, Maris JM. Neuroblastoma. In: Principles and Practice of Pediatric Oncology, Pizzo PA, Poplack DG (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. p.886.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25386934" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Neuroblastoma: molecular pathogenesis and therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25386934" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Neuroblastoma: molecular pathogenesis and therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10363850" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12580370" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Malignant abdominal masses in children: quick guide to evaluation and diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2403727" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29528815" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Updates in Diagnosis, Management, and Treatment of Neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2233519" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Superior vena cava syndrome associated with childhood malignancy: analysis of 24 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3244095" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Congenital cervical neuroblastoma associated with Horner syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3343639" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Horner's syndrome in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9536881" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Does Horner's syndrome in infancy require investigation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6493702" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Ocular involvement in neuroblastoma: prognostic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17011859" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Pediatric horner syndrome: etiologies and roles of imaging and urine studies to detect neuroblastoma and other responsible mass lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7371035" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Urinary excretion of 3-methoxy-4-hydroxymandelic acid and 3-methoxy-4-hydroxyphenylacetic acid by 288 patients with neuroblastoma and related neural crest tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23830883" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Analysis of vanillylmandelic acid and homovanillic acid by UPLC-MS/MS in serum for diagnostic testing for neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23813598" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Interchangeability between 24-hour collection and single spot urines for vanillylmandelic and homovanillic acid levels in the diagnosis of neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21460401" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Investigating neuroblastoma in childhood opsoclonus-myoclonus syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6101297" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Vasoactive intestinal peptide secreting tumors of childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7186023" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Rapid changes of serum vasoactive intestinal peptide after removal of ganglioneuroblastoma with watery-diarrhea-hypokalemia-achlorhydria syndrome in a child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2170900" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : VIP secreting tumours in infancy. A review of radiological appearances.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9143388" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Lung involvement in neuroblastoma: incidence and characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6875712" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Coagulopathy of disseminated neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7062895" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Myelofibrosis in neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/543514" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The multiple hematologic manifestations of neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5431211" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Blanching subcutaneous nodules in neonatal neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7068966" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Infantile neuroblastoma presenting with cutaneous blanching nodules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10943267" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Pediatric skin tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8361790" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Prenatal detection of neuroblastoma: a ten-year experience from the Dana-Farber Cancer Institute and Children's Hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8308685" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Fetal neuroblastoma: prenatal diagnosis and natural history.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9217044" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Prenatally diagnosed neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8632270" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Spontaneous resolution of antenatally diagnosed adrenal masses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6876021" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : [Retroperitoneal neuroblastoma diagnosed in utero. Apropos of 1 case].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17874681" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Pediatric spinal cord tumors and masses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1394242" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The neurobiology of the opsoclonus-myoclonus syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8879053" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Opsoclonus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1313677" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Opsoclonus-myoclonus with Beckwith-Wiedemann syndrome and hepatoblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11940712" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Opsoclonus-myoclonus syndrome following Epstein-Barr virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7594265" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Opsoclonus myoclonus syndrome secondary to Epstein-Barr virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10841099" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Opsoclonus-myoclonus syndrome in a child with neuroborreliosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2360961" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Central nervous system manifestations of parainfluenza virus type 3 infections in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9640838" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Opsoclonus-myoclonus associated with traditional medicine ingestion: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2614455" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Opsoclonus-myoclonus following the intranasal usage of cocaine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4073856" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Syndrome of opsoclonus-myoclonus in hyperosmolar nonketotic coma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6299176" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Syndrome of opsoclonus-myoclonus caused by Coxsackie B3 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35086681" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Comparing safety and adequacy between surgical biopsy versus core needle biopsy in diagnosing neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8336186" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15173520" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Guidelines for pediatric cancer centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19185008" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : (123)I-mIBG scintigraphy in patients with known or suspected neuroblastoma: Results from a prospective multicenter trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33629142" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Prognostic significance of pretreatment 18F-FDG positron emission tomography/computed tomography in pediatric neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21586679" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30344783" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Value of SPECT/CT in Diagnostic I-131 MIBG Scintigraphy in Patients with Neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9544682" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Current concepts on the diagnostic use of MIBG in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10029806" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Clinical impact and prognostic value of metaiodobenzylguanidine imaging in children with metastatic neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4009283" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Iodine-131 metaiodobenzylguanidine scintigraphy for the location of neuroblastoma: preliminary experience in ten cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3991738" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Detection of neuroblastoma with 131I-meta-iodobenzylguanidine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19805691" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11932913" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : High incidence of thyroid dysfunction despite prophylaxis with potassium iodide during (131)I-meta-iodobenzylguanidine treatment in children with neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8635072" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Primary hypothyroidism as a consequence of 131-I-metaiodobenzylguanidine treatment for children with neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1991264" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Treatment of advanced neuroblastoma with I-131 meta-iodobenzylguanidine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19047290" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19047291" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11932471" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Neuroblastoma screening at one year of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11870162" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Marginal decrease in mortality and marked increase in incidence as a result of neuroblastoma screening at 6 months of age: cohort study in seven prefectures in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11932470" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Screening of infants and mortality due to neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14615452" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Neuroblastoma mass screening in late infancy: insights into the biology of neuroblastic tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15750929" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Profile of neuroblastoma detected by mass screening, resected after observation without treatment: results of the Wait and See pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22964741" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
